BCL2L1 and leukemia: In summary, both the non-selective BCL-2/BCL-XL inhibitor ABT737 and the selective BCL-XL inhibitor A1155463 exerted synergism to kill JMML cells in combination with azacitidine, and additionally targeted leukemia-initiating cells better than azacitidine.